Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AK 129

Next Previous
X
Search
Drug Profile

AK 129

Alternative Names: AK-129

Latest Information Update: 30 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 Sep 2024 Akeso plans to initiated a phase I/II trial for Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (Monotherapy, Combination therapy, First-line therapy, Inoperabel/unresectable, Metastatic disease) in China (IV) (NCT06586294)
  • 02 Mar 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) (IV) (NCT05645276)
  • 13 Dec 2022 Akeso plans a phase Ia/Ib trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in January 2023 (IV, Infusion) (NCT05645276)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top